REVA Medical : to Present at Canaccord Genuity Forum

REVA Medical to Present at the Canaccord Genuity

Medical Technologies & Diagnostics Forum

San Diego, California (Wednesday, November 14, 2018 - PST) - REVA Medical, Inc. (ASX: RVA) ("REVA" or the "Company"), a leader in bioresorbable polymer technologies for vascular medical applications, is pleased to announce that its Chief Executive Officer, Reggie Groves, is scheduled to present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15, 2018 in New York City.

The presentation delivered at the conference is available in the Investor Relations section of REVA's website atwww.revamedical.com and will be presented from time to time by the Company at various other investor and analyst meetings.

About REVA Medical

REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company's lead products are the Fantom and Fantom Encore bioresorbable vascular scaffolds for the treatment of coronary artery disease. REVA is currently selling Fantom in Germany, Switzerland, Austria, the Netherlands, Belgium, Luxembourg, Italy and Turkey. REVA is based in San Diego, California, and employs 45 people in the U.S. and Europe.

Fantom, Fantom Encore, MOTIV and Tyrocore are trademarks of REVA Medical, Inc.

United States	Australia	Australia
Investor & Media Enquiries:	Investor Enquiries:	Media Enquiries:
REVA Medical, Inc.	Perpetuity Capital Pty Ltd	Buchan Consulting
Brandi Roberts	Kim Jacobs	Rebecca Wilson
Chief Financial Officer	[phone]	[phone]
[phone]	Andrew Cohen
[phone]
David Schull
Russo Partners
[phone]
[e-mail]

HEAD OFFICE: 5751 Copley Drive, San Diego, CA 92111 • [phone] • [phone] (FAX) •www.revamedical.com

AUSTRALIAN OFFICE: Suite 4, Level 14, 6 O'Connell Street, Sydney NSW 2000 • [phone] • ARBN 146 505 777